OncoMatch/Clinical Trials/NCT06749899
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Is NCT06749899 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including QL1706 and Gemcitabine for nasopharyngeal cancinoma (npc).
Treatment: QL1706 · Gemcitabine · Cisplatin — The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T4N1, T1-4N2-3, STAGE II: T1-3N2, STAGE III: T1-4N3, STAGE III: T4N1-2 (AJCC 9th)
Tumor staged as T4N1 and T1-4N2-3 (AJCC 9th) * Stage II: T1-3N2 * Stage III: T1-4N3, T4N1-2
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
white blood cell count > 4 × 10⁹/L; hemoglobin >90g/L; platelet count >100×10⁹/L
Kidney function
clearance rate ≥ 60 ml/min
Liver function
Total bilirubin ≤ 1.5 × ULN; ALT/AST ≤2.5×ULN; Alkaline phosphatase ≤ 2.5 × ULN
Cardiac function
Normal cardiac enzyme tests and ECG; for patients with abnormal ECG findings or prior cardiovascular disease, additional assessments (myocardial function evaluation and cardiac ultrasound) must be within normal limits
Adequate marrow function: white blood cell count > 4 × 10⁹/Lhemoglobin >90g/L and platelet count >100×10⁹/L Adequate hepatic and renal function： * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) * Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×ULN * Alkaline phosphatase ≤ 2.5 × ULN * clearance rate ≥ 60 ml/min Other laboratory and clinical criteria * Normal thyroid function, serum amylase and lipase, pituitary hormone levels, inflammatory markers, cardiac enzyme tests and electrocardiogram (ECG) * For patients aged >50 years with a history of smoking, normal pulmonary function test (PFT) results are required * For patients with abnormal ECG findings or a prior history of cardiovascular disease (not meeting any exclusion criteria listed in Item 8), additional assessments including myocardial function evaluation and cardiac ultrasound (echocardiography) must be performed, with results within normal limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify